| NCT ID | NCT05968417 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Institute of Cancer Research, United Kingdom |
| Condition | Multiple Myeloma |
| Study Type | OBSERVATIONAL |
| Enrollment | 250 participants |
| Start Date | 2020-07-22 |
| Primary Completion | 2033-02-28 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 250 participants in total. It began in 2020-07-22 with a primary completion date of 2033-02-28.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Myeloma is a bone marrow cancer with over 5000 patients diagnosed in the UK each year. Researchers are committed to improving understanding of myeloma and developing more effective treatments with fewer side effects in order to improve patient outcomes. In order to do this, researchers are collecting samples of blood and bone marrow to test the activity of potential new treatments in the laboratory and to understand what may be the cause of some treatments not working.
Eligibility Criteria
Inclusion Criteria: 1. Participants who have a diagnosis, or suspected diagnosis, of myeloma or related plasma cell disorder 2. Participants who are undergoing a peripheral blood or bone marrow aspirate sampling for diagnostic, staging or follow-up purposes, before, whilst or after receiving anti-myeloma treatment 3. Participants aged 18 years of age or above 4. Participants willing to consent to an additional sample being taken at the time of their peripheral blood or bone marrow aspirate sampling Exclusion Criteria: 1. Participants unable to provide consent 2. Participants with known active infectious diseases (e.g. HIV, Hepatitis B/C, COVID) that pose a risk to the use of the sample in the laboratory
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05968417 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Multiple Myeloma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05968417 currently recruiting?
Yes, NCT05968417 is actively recruiting participants. Contact the research team at Disco.iras263630@nhs.net for enrollment information.
Where is the NCT05968417 trial being conducted?
This trial is being conducted at Sutton, United Kingdom.
Who is sponsoring the NCT05968417 clinical trial?
NCT05968417 is sponsored by Institute of Cancer Research, United Kingdom. The trial plans to enroll 250 participants.